Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.46 |
| ▸ | CPA3 | P15088 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.40 |
| ▸ | PTPRA | P18433 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2368283 | 0.83 | FOLH1 (0.54) | FOLH1CPA3GRM3NAALAD2 | |
| SCHEMBL2368044 | 0.81 | FOLH1 (0.44) | FOLH1CPA3SMN1; SMN2GRM3NAALAD2 | |
| SCHEMBL2368621 | 0.80 | FOLH1 (0.43) | FOLH1CPA3SMN1; SMN2GRM3NAALAD2 | |
| SCHEMBL1373533 | 0.77 | GRM3 (0.55) | FOLH1GRM3 | |
| SCHEMBL2368228 | 0.76 | SMN1; SMN2 (0.42) | FOLH1SMN1; SMN2PTPRAALDH1A1CYP1A2 | |
| SCHEMBL5054263 | 0.76 | GRM3 (0.57) | FOLH1CPA3GRM3PTPRA | |
| SCHEMBL2368164 | 0.75 | FOLH1 (0.50) | FOLH1CPA3GRM3NAALAD2 | |
| SCHEMBL7607528 | 0.75 | GRM3 (0.52) | FOLH1GRM3 | |
| SCHEMBL2368565 | 0.74 | FOLH1 (0.50) | FOLH1CPA3SMN1; SMN2 | |
| SCHEMBL5059809 | 0.74 | FOLH1 (0.52) | FOLH1CPA3GRM3NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091693-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2024-09-17 | — | — | US | disclosed |
| US-20220098564-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2022-03-31 | — | — | US | disclosed |
| US-11155800-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200283748-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2020-09-10 | — | — | US | disclosed |
| US-10557128-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190002861-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2019-01-03 | — | — | US | disclosed |
| US-9951324-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160151508-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2016-06-02 | — | — | US | disclosed |
| US-20120322741-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2011106639-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098564-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CPA3 521/4885SMN1; SMN2 3284/4885 |
| US-20200283748-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CPA3 521/4885SMN1; SMN2 3284/4885 |
| US-11155800-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CPA3 521/4885SMN1; SMN2 3284/4885 |
| US-12091693-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CPA3 521/4885SMN1; SMN2 3284/4885 |
| US-20120322741-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CPA3 521/4885SMN1; SMN2 3284/4885 |
| US-20160151508-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CPA3 521/4885SMN1; SMN2 3284/4885 |
| US-10557128-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CPA3 521/4885SMN1; SMN2 3284/4885 |
| US-20190002861-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CPA3 521/4885SMN1; SMN2 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.